|
Market Closed -
Nasdaq
16:00:00 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 35.06 USD | -2.41% |
|
+0.19% | -49.58% |
Company Valuation: Structure Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,991 | 1,553 | 4,809 | 2,500 | - | - |
| Change | - | -22.02% | 209.65% | -48% | - | - |
| Enterprise Value (EV) 1 | 1,991 | 669.4 | 3,362 | 1,533 | 1,941 | 2,498 |
| Change | - | -66.38% | 402.31% | -54.4% | 26.61% | 28.7% |
| P/E | -50.3x | -34.8x | -86.9x | -21.7x | -16x | -20.7x |
| PBR | - | 5.39x | 9.75x | 6.89x | 11.5x | 40.3x |
| PEG | 0.6x | 9.4x | -33.89x | -0x | -0.5x | 0.9x |
| Capitalization / Revenue | - | - | - | 60x | 55,016x | 16.4x |
| EV / Revenue | - | - | - | 36.8x | 42,712x | 16.4x |
| EV / EBITDA | - | -4.26x | -11.8x | -3.39x | -3.79x | -4.73x |
| EV / EBIT | -19.4x | -4.23x | -11.7x | -3.39x | -3.57x | -5.72x |
| EV / FCF | -24.4x | -5.68x | -14.9x | -4.09x | -5.03x | -5.48x |
| FCF Yield | -4.1% | -17.6% | -6.72% | -24.5% | -19.9% | -18.2% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.81 | -0.78 | -0.8 | -1.616 | -2.186 | -1.69 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 41.67 | 0.0454 | 152.6 |
| EBITDA 1 | - | -157.2 | -285.5 | -451.7 | -511.6 | -527.9 |
| EBIT 1 | -102.8 | -158.2 | -286.8 | -452 | -544.2 | -436.8 |
| Net income 1 | -89.62 | -122.5 | -141.2 | -313.8 | -471 | -336.7 |
| Net Debt 1 | - | -883.5 | -1,446 | -967.2 | -559.2 | -2.073 |
| Reference price 2 | 40.76 | 27.12 | 69.55 | 35.06 | 35.06 | 35.06 |
| Nbr of stocks (in thousands) | 48,855 | 57,261 | 69,139 | 71,310 | - | - |
| Announcement Date | 3/8/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -22.23x | 38.28x | -3.53x | -.--% | 2.56B | |
| 21.09x | 7.53x | 15.13x | 1.41% | 72.26B | |
| 31.3x | 9.02x | 28.11x | 0.04% | 60.24B | |
| 32.1x | 6.85x | 17.78x | -.--% | 27.73B | |
| -72.3x | 13.87x | -75.56x | -.--% | 25.73B | |
| -15.17x | 5.73x | -7.2x | -.--% | 24.75B | |
| 28.46x | 5.35x | 17.81x | -.--% | 20.74B | |
| 42.74x | 15.97x | 32.4x | 0.35% | 15.06B | |
| 17.96x | 5.35x | 12.5x | -.--% | 14.41B | |
| 1015.79x | 35.53x | 613.78x | -.--% | 14.23B | |
| Average | 107.97x | 14.35x | 65.12x | 0.18% | 27.77B | |
| Weighted average by Cap. | 64.65x | 10.11x | 39.32x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GPCR Stock
- Valuation Structure Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
